Deva Holding AS Total Assets
Deva Holding AS total assets. Based on the latest financial reports, Deva Holding AS (DEVA) holds total assets worth TL35.50 Billion TRY (≈ $795.16 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how efficiently does Deva Holding AS generate cash for how efficiently the company converts equity into cash flow.
Total Assets of Deva Holding AS (2005–2024)
Total assets of Deva Holding AS from 2005 to 2024. This chart illustrates how Deva Holding AS's total assets have evolved over time, based on quarterly financial data. See DEVA live share price for real-time trading data and today's change.
Deva Holding AS - Asset Composition Analysis
Deva Holding AS Total Assets Breakdown (December 2024)
Deva Holding AS total assets breakdown as of December 2024. Deva Holding AS's total assets of TL35.50 Billion consist of 41.3% current assets and 58.7% non-current assets. Explore Deva Holding AS current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (TRY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | TL0.00 | 3.2% |
| Accounts Receivable | TL4.93 Billion | 16.6% |
| Inventory | TL4.73 Billion | 15.9% |
| Property, Plant & Equipment | TL0.00 | 0.0% |
| Intangible Assets | TL5.86 Billion | 19.7% |
| Goodwill | TL30.86 Million | 0.1% |
Asset Composition Trend (2005–2024)
This chart illustrates how Deva Holding AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Deva Holding AS's current assets represent 41.3% of total assets in 2024, an increase from 0.0% in 2005.
- Cash Position: Cash and equivalents constituted 3.2% of total assets in 2024, up from 2.2% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 4.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 19.7% of total assets.
Deva Holding AS Competitors by Total Assets
Key competitors of Deva Holding AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.94 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
Deva Holding AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.71 | 1.57 | 1.97 |
| Quick Ratio | 1.06 | 0.95 | 1.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | TL6.02 Billion | TL4.49 Billion | TL961.62 Million |
Deva Holding AS - Advanced Valuation Insights
This section examines the relationship between Deva Holding AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.49 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -8.3% |
| Total Assets | TL29.73 Billion |
| Market Capitalization | $329.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values Deva Holding AS's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Deva Holding AS's assets decreased by 8.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Deva Holding AS (2005–2024)
The table below shows the annual total assets of Deva Holding AS from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | TL29.73 Billion ≈ $665.86 Million |
-8.26% |
| 2023-12-31 | TL32.40 Billion ≈ $725.77 Million |
+275.73% |
| 2022-12-31 | TL8.62 Billion ≈ $193.16 Million |
+69.77% |
| 2021-12-31 | TL5.08 Billion ≈ $113.78 Million |
+64.51% |
| 2020-12-31 | TL3.09 Billion ≈ $69.16 Million |
+45.69% |
| 2019-12-31 | TL2.12 Billion ≈ $47.47 Million |
+27.03% |
| 2018-12-31 | TL1.67 Billion ≈ $37.37 Million |
+32.79% |
| 2017-12-31 | TL1.26 Billion ≈ $28.14 Million |
+23.48% |
| 2016-12-31 | TL1.02 Billion ≈ $22.79 Million |
+2.47% |
| 2015-12-31 | TL992.95 Million ≈ $22.24 Million |
+11.13% |
| 2014-12-31 | TL893.53 Million ≈ $20.01 Million |
+8.09% |
| 2013-12-31 | TL826.63 Million ≈ $18.51 Million |
+14.29% |
| 2012-12-31 | TL723.26 Million ≈ $16.20 Million |
+8.56% |
| 2011-12-31 | TL666.25 Million ≈ $14.92 Million |
+6.98% |
| 2010-12-31 | TL622.80 Million ≈ $13.95 Million |
+17.86% |
| 2009-12-31 | TL528.42 Million ≈ $11.84 Million |
+7.89% |
| 2008-12-31 | TL489.79 Million ≈ $10.97 Million |
+27.13% |
| 2007-12-31 | TL385.28 Million ≈ $8.63 Million |
+32.45% |
| 2006-12-31 | TL290.88 Million ≈ $6.52 Million |
+6.48% |
| 2005-12-31 | TL273.18 Million ≈ $6.12 Million |
-- |
About Deva Holding AS
Deva Holding A.S. manufactures, markets, and sells pharmaceutical products in Turkey. The company offers antineoplastic and immunomodulating agents; dermatological products; sysyemic hormanal preparations; anti-infective and antiparasitic products for systemic use; food supplements; and electrolyte solutions. It also provides products in the areas of urogenital system and sex hormones, blood and … Read more